BACKGROUND: Over the years quantification of cytomegalovirus (HCMV) load in blood has become a mainstay of clinical management helping direct deployment of antiviral therapy, assess response to therapy and highlight cases of drug resistance. AIMS: The review focuses on a brief historical perspective of HCMV quantification and the ways in which viral load is being used to improve patient management. METHODS: A review of the published literature and also personal experience at the Royal Free Hospital. RESULTS: Quantification of HCMV is essential for efficient patient management. The ability to use real time quantitative PCR to drive pre-emptive therapy has improved patient management after transplantation although the threshold viral loads for deployment differ between laboratories. The field would benefit from access to a universal standard for quantification. CONCLUSIONS: We see that HCMV quantification will continue to be central to delivering individualised patient management and facilitating multicentre trials of new antiviral agents and vaccines in a variety of clinical settings.
BACKGROUND: Over the years quantification of cytomegalovirus (HCMV) load in blood has become a mainstay of clinical management helping direct deployment of antiviral therapy, assess response to therapy and highlight cases of drug resistance. AIMS: The review focuses on a brief historical perspective of HCMV quantification and the ways in which viral load is being used to improve patient management. METHODS: A review of the published literature and also personal experience at the Royal Free Hospital. RESULTS: Quantification of HCMV is essential for efficient patient management. The ability to use real time quantitative PCR to drive pre-emptive therapy has improved patient management after transplantation although the threshold viral loads for deployment differ between laboratories. The field would benefit from access to a universal standard for quantification. CONCLUSIONS: We see that HCMV quantification will continue to be central to delivering individualised patient management and facilitating multicentre trials of new antiviral agents and vaccines in a variety of clinical settings.
Authors: Devon J Shedlock; Kendra T Talbott; Stephan J Wu; Christine M Wilson; Karuppiah Muthumani; Jean D Boyer; Niranjan Y Sardesai; Sita Awasthi; David B Weiner Journal: Hum Vaccin Immunother Date: 2012-11-01 Impact factor: 3.452
Authors: R T Hayden; J Preiksaitis; Y Tong; X Pang; Y Sun; L Tang; L Cook; S Pounds; J Fryer; A M Caliendo Journal: J Clin Microbiol Date: 2015-08-12 Impact factor: 5.948
Authors: S F Atabani; C Smith; C Atkinson; R W Aldridge; M Rodriguez-Perálvarez; N Rolando; M Harber; G Jones; A O'Riordan; A K Burroughs; D Thorburn; J O'Beirne; R S B Milne; V C Emery; P D Griffiths Journal: Am J Transplant Date: 2012-05-17 Impact factor: 8.086
Authors: Simnikiwe H Mayaphi; Marieke Brauer; Daniel M Morobadi; Ahmad H Mazanderani; Rendani T Mafuyeka; Steve A S Olorunju; Gregory R Tintinger; Anton Stoltz Journal: PLoS One Date: 2014-04-03 Impact factor: 3.240